The New Orleans Pelicans, as we know them, hinge on a medical report. It may sound dramatic and overstated, but with the availability of Anthony Davis mired in the murky waters of medical terminology, the stakes of his diagnosis are nearly impossible to overemphasize in the context of this franchise. Even a reworked Pelicans’ roster, highlighted by All-Star center DeMarcus Cousins and point guard Rajon Rondo, simply doesn’t have enough firepower to compete for the top half of the Western Conference standings without Davis. And when the All-NBA forward plopped to the ground like a ton of bricks Friday, after receiving ever-so-slight contact from Utah center Derrick Favors, it was an ominous sign. When Davis couldn’t get off of the floor on his own power and was reportedly taken to the locker room via wheelchair, the foreboding signal was even worse. Yet Pelicans officials said the MRI Davis underwent Saturday in Portland failed to reveal the full scope of severity, forcing the team to wait until Sunday to make a true determination on just how long Davis could be sidelined. “He’s got a groin pull and we’re not sure the extent of it yet,” coach Alvin Gentry told reporters before Saturday’s game against the Trail Blazers. “He had an MRI that was a little inconclusive, but he will take one when we get back to New Orleans and we’ll find out the full depth of the injury.” It’s hard to imagine the anxiety flowing through Gentry and general manager Dell Demps in the meantime. Just last week, it looked like the Pelicans had finally clicked. Three consecutive victories, including impressive home comebacks over the Oklahoma City Thunder and San Antonio Spurs, started to catch the league’s attention and drove New Orleans a game out of the No. 3 spot in the West. Davis won the Western Conference Player of the Week award, punishing opponents from all angles. And if the eye test weren’t obvious enough, the numbers clearly demonstrate Davis’ value to the Pelicans.
The Pelicans' season could hinge on Anthony Davis' injury
The Advocate | Dec 4